UBS AG has given Gerresheimer AG a "Buy" rating with a target price of 132 euros for the company's shares, which are currently trading at 73.85 euros, down 0.27%.

Analyst Olivier Calvet believes that data from Novo Nordisk's weight-loss drug CagriSema could significantly impact Gerresheimer's stock price.

Gerresheimer is an important supplier in the packaging and syringe sector. Calvet prefers Gerresheimer over competitor Ypsomed, as other firms like Schott Pharma and Stevanto are not directly affected by the developments surrounding CagriSema.

The analysis was published on November 29, 2024, and reflects UBS's confidence in Gerresheimer's market position and potential growth opportunities resulting from recent advancements in the pharmaceutical industry.